Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial.
Br J Cancer
; 105(9): 1273-8, 2011 Oct 25.
Article
em En
| MEDLINE
| ID: mdl-21959871
ABSTRACT
BACKGROUND:
We performed a cost-effectiveness analysis of trastuzumab plus chemotherapy for human epidermal growth factor type-2 (HER2)-positive advanced gastric cancer (GC) based on data obtained from the Trastuzumab for Gastric Cancer (ToGA) trial from a Japanese perspective.METHODS:
The following Japanese and Korean populations of the ToGA trial were analysed to obtain mean overall and progression-free survival times (1) all HER2-positive populations, (2) immunohistochemical (IHC) 2+/fluorescence in situ hybridisation (FISH)+ or IHC 3+ populations, and (3) IHC 3+ only population. The effect of trastuzumab treatment on mean survival time was estimated by fitting a Weibull parametric function. Costs were calculated from the perspective of health-care payer. Neither costs nor outcomes were discounted because of short life expectancy.RESULTS:
In the base-case analysis, the incremental cost-effectiveness ratio was (1) JPY 12 million (110,000) per quality-adjusted life year (QALY) gained and JPY 8.9 million (81,000) per life-year gained (LYG) for all HER2-positive populations, (2) JPY 9.1 million (83,000) per QALY gained and JPY 6.6 million (60,000) per LYG for the IHC 2+/FISH+ or IHC 3+ population, and (3) JPY 6.1 million (55,000) per QALY gained and JPY 4.3 million (39,000) per LYG for the IHC 3+ population.CONCLUSION:
Trastuzumab treatment for IHC 3+ populations is cost effective. Our analysis can find a cost-effective subgroup when advanced GC is treated by trastuzumab.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
Tipo de estudo:
Clinical_trials
/
Health_economic_evaluation
Aspecto:
Patient_preference
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
Asia
Idioma:
En
Revista:
Br J Cancer
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Japão